We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Macrophage Nanoparticles Created as Sepsis Treatment

By LabMedica International staff writers
Posted on 16 Jan 2018
A novel approach for treating sepsis is based on nanoparticles (so-called nanosponges) coated with cell membranes isolated from immune macrophages.

Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs. More...
Sepsis is caused by an immune response triggered by an infection. Most commonly, the infection is bacterial, but it may also be from fungi, viruses, or parasites. Common locations for the primary infection include lungs, brain, urinary tract, skin, and abdominal organs.

Currently, there are no effective clinically available sepsis treatments, and care remains primarily supportive. In an effort to develop an effective sepsis treatment, investigators at the University of California, San Diego (USA) fabricated a novel type of macrophage biomimetic nanoparticle or nanosponge. The nanoparticles, made by wrapping polymeric cores with cell membrane derived from macrophages, possessed an antigenic exterior the same as the source cells.

The investigators reported in the October 24, 2017, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences that by acting as macrophage decoys, these nanoparticles bound and neutralized endotoxins that would otherwise have triggered immune activation. In addition, these macrophage-like nanoparticles sequestered proinflammatory cytokines and inhibited their ability to potentiate the sepsis cascade.

In a mouse Escherichia coli bacteremia model, treatment with macrophage mimicking nanoparticles, termed M-Phi-NPs, reduced proinflammatory cytokine levels, inhibited bacterial dissemination, and ultimately conferred a significant survival advantage to infected mice.

"A wide range of endotoxins and pro-inflammatory cytokines naturally bind to macrophage cell membranes, so these nanosponges serve as universal traps for a broad spectrum of sepsis-causing molecules," said senior author Dr. Liangfang Zhang, professor of nanoengineering at the University of California, San Diego. "They can work across different bacterial genus, species and strains, and since they are covered in actual macrophage cell membranes, they can pass as the body's own immune cells and circulate the bloodstream without being evicted."

Related Links:
University of California, San Diego


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.